"Fairly predictive tests for Alzheimer's disease, schizophrenia, depression, some malignancies, heart disease, and most of the rest of the major killers and disablers will probably be in place by 2000 to 2010. Many if not most of these ailments will be assessable in terms of a very sophisticated genetic risk profile which it will be possible to generate in infancy or childhood (or in utero)." In 1987, cryonics advocate Mike Darwin wrote about the next twenty years of medicine.
The emergence of a citation cartel. "Cell Transplantation is a medical journal published by the Cognizant Communication Corporation of Putnam Valley, New York. In recent years, its impact factor has been growing rapidly. In 2006, it was 3.482. In 2010, it had almost doubled to 6.204. When you look at which journals cite Cell Transplantation, two journals stand out noticeably: the Medical Science Monitor, and The Scientific World Journal. According to the JCR, neither of these journals cited Cell Transplantation until 2010. Then, in 2010, a review article was published in the Medical Science Monitor citing 490 articles, 445 of which were to papers published in Cell Transplantation. All 445 citations pointed to papers published in 2008 or 2009 — the citation window from which the journal’s 2010 impact factor was derived. Of the remaining 45 citations, 44 cited the Medical Science Monitor, again, to papers published in 2008 and 2009. Three of the four authors of this paper sit on the editorial board of Cell Transplantation. Two are associate editors, one is the founding editor. The fourth is the CEO of a medical communications company." (from Scholarly Kitchen, via Andrew Gelman.)
Mercenary Epidemiology: Data Reanalysis and Reinterpretation for Sponsors With Financial Interest in the Outcome. (.pdf link) When should scientists be required to release their raw data for (potentially hostile) re-analysis? A letter to the editors of Annals of Epidemiology from David Michaels, Ph.D., MPH, public health blogger, author of the book Doubt Is Their Product, and, as of December 2009, the Assistant Secretary of Labor for OSHA, unanimously confirmed by the Senate despite the dismay of some. Michaels interviewed at Science Progress about Doubt Is Their Product (podcast, with transcript.)
"We were concerned that the study would raise a lot of controversy and be misused," Pardo said. "We were right." Some practitioners treat autistic children with the anti-inflammatory intravenous immunoglobulin, citing a study by Carlos Pardo, et al. showing inflammation in the brains of deceased autistic patients. Pardo: "modulators of immune reactions (e.g. intravenous immunoglobulins, IVIG) WOULD NOT HAVE a significant effect." Others, following the work of Simon Baron-Cohen on autism and the male brain, treat autistic children with testosterone inhibitors, a prospect which Baron-Cohen says "fills me with horror." Another anti-inflammatory treatment, hyperbaric therapy, is supported by one recent clinical trial, but looks bad in another. Side effects include horrible death by fire. (via the Chicago Tribune)